A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and D

Grants and Contracts Details

StatusActive
Effective start/end date3/15/222/20/23

Funding

  • Janssen Research and Development LLC: $24,950.00